Meeting
2015 ASCO Annual Meeting
Exploring the intra-patient PIK3CA mutational heterogeneity of circulating tumour cells by massive parallel sequencing in patients with metastatic hormone receptor-positive breast cancer.
Authors
Bram De Laere
Center for Oncological Research (CORE) - campus Sint-Augustinus - University of Antwerp, Antwerpen, Belgium
Bram De Laere , Dieter J E Peeters , Roberto Salgado , Peter B Vermeulen , Peter A van Dam , Steven J Van Laere , Luc Yves Dirix
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Circulating Tumor Cells
Citation
J Clin Oncol 33, 2015 (suppl; abstr 11030)
DOI
10.1200/jco.2015.33.15_suppl.11030
Abstract #
11030
Poster Bd #
242
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Evaluation of PI3K-pathway–activation status in matched primary (P) and metastatic (M) ER+/HER2- breast cancer (BC) lesions according to PIK3CA-mutation status.
First Author: Debora Fumagalli
Poster
2011 ASCO Annual Meeting
Improving detection methods for PIK3CA mutations in breast cancer using peripheral blood from patients with metastastic breast cancer (MBC).
First Author: M. J. Higgins
Poster
2023 ASCO Annual Meeting
Multi-factor dynamic analysis of ctDNA and CTC to aid the diagnostic prognosis of patients with metastatic breast cancer (MBC).
First Author: Qiang Zhang
Poster
2023 ASCO Annual Meeting
A phase 1b/2 dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and/or metastatic estrogen receptor–positive (ER+)/HER2-negative (HER2-) breast cancer.
First Author: Virginia F. Borges